On Friday, CytomX Therapeutics Inc (NASDAQ: CTMX) was 5.63% up from the session before settling in for the closing price of $1.42. A 52-week range for CTMX has been $1.04 – $5.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 28.25%. When this article was written, the company’s average yearly earnings per share was at -1825.60%. With a float of $73.11 million, this company’s outstanding shares have now reached $77.92 million.
Let’s determine the extent of company efficiency that accounts for 122 employees.
CytomX Therapeutics Inc (CTMX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward CytomX Therapeutics Inc stocks. The insider ownership of CytomX Therapeutics Inc is 6.17%, while institutional ownership is 67.17%. The most recent insider transaction that took place on Mar 19 ’24, was worth 42,175. In this transaction CEO of this company sold 20,223 shares at a rate of $2.09, taking the stock ownership to the 524,481 shares. Before that another transaction happened on Mar 19 ’24, when Company’s SVP, Chief Scientific Officer sold 12,795 for $2.09, making the entire transaction worth $26,684. This insider now owns 168,579 shares in total.
CytomX Therapeutics Inc (CTMX) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 3/31/2024, it has been observed that the corporation posted -0.02 earnings per share (EPS) during the time that was better than consensus figure (set at -0.2) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1825.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 67.21% growth over the previous five years of trading.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
You can see what CytomX Therapeutics Inc (CTMX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.20, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Looking closely at CytomX Therapeutics Inc (NASDAQ: CTMX), its last 5-days average volume was 0.52 million, which is a drop from its year-to-date volume of 3.51 million. As of the previous 9 days, the stock’s Stochastic %D was 60.00%. Additionally, its Average True Range was 0.10.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 7.84%, which indicates a significant decrease from 91.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.25% in the past 14 days, which was lower than the 224.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5148, while its 200-day Moving Average is $1.6985. However, in the short run, CytomX Therapeutics Inc’s stock first resistance to watch stands at $1.5298. Second resistance stands at $1.5597. The third major resistance level sits at $1.6093. If the price goes on to break the first support level at $1.4503, it is likely to go to the next support level at $1.4007. Now, if the price goes above the second support level, the third support stands at $1.3708.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
There are 77,919K outstanding shares of the company, which has a market capitalization of 116.88 million. As of now, sales total 101,210 K while income totals -570 K. Its latest quarter income was 41,460 K while its last quarter net income were 13,790 K.
